IMRX
NASDAQImmuneering Corporation
Price$4.63-0.02 (-0.43%)
01:30 PM07:45 PM
News · 26 weeks44-50%
2026-01-182026-07-12
Mix2690d
- Insider9(35%)
- SEC Filings7(27%)
- Other6(23%)
- Earnings2(8%)
- Offering1(4%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Chief Financial Officer Gengos Andrew4 - Immuneering Corp (0001790340) (Issuer)
- PRImmuneering Corporation Announces Grants of Inducement AwardsNEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the "Start Date"). In connection with the commencement of Mr. Gengos’s employment, on July 16, 2026, Mr. Gengos was granted an option to purchase 650,000 shares of the Company’s Class A common stock ("Common Stock") with a per share exercise price of $4.78, the closing trading price of the Common Stock on the Nasdaq Global Market on July 16, 2026 (the "Closing Price").
- INSIDERNew insider Gengos Andrew claimed ownership of 225,000 shares (SEC Form 3)3 - Immuneering Corp (0001790340) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Immuneering with a new price targetCantor Fitzgerald initiated coverage of Immuneering with a rating of Overweight and set a new price target of $17.00
- PRKalaris Appoints Laurie Keating to Board of DirectorsBERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In conjunction with the announcement of Ms. Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board of Directors. "We’re delighted to welcome Laurie to the Kalaris Board of Directors. She has extensive strategic, operational, and legal expertise spanning multiple therapeutic areas and development stages. Laurie will be
- INSIDERPRESIDENT AND CEO Zeskind Benjamin J. bought $10,948 worth of shares (2,400 units at $4.56), increasing direct ownership by 0.10% to 2,315,252 units (SEC Form 4)4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $25,045 worth of shares (6,035 units at $4.15), increasing direct ownership by 2% to 382,531 units (SEC Form 4)4 - Immuneering Corp (0001790340) (Issuer)
- SECImmuneering Corporation filed SEC Form 8-K: Leadership Update8-K - Immuneering Corp (0001790340) (Filer)
- PRImmuneering Appoints Andrew Gengos as Chief Financial Officer- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Mr. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion. At Immuneering, Mr. Gengos will oversee financial strategy, capital allocation, in
- INSIDERSEC Form 4 filed by Director Schall Thomas J.4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERSEC Form 4 filed by Director Hausman Diana4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERSEC Form 4 filed by Director Carpenter Robert J4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERSEC Form 4 filed by Director Keating Laurie4 - Immuneering Corp (0001790340) (Issuer)
- INSIDERSEC Form 4 filed by Director Feinberg Peter4 - Immuneering Corp (0001790340) (Issuer)
- SECImmuneering Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Immuneering Corp (0001790340) (Filer)
- PRImmuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic CancerGlobal pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endpoint of overall survival, anticipated in mid-2028 NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that the first patient has been dosed in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer patien
- SECImmuneering Corporation filed SEC Form 8-K: Other Events8-K - Immuneering Corp (0001790340) (Filer)
- PRImmuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related adverse events occurring in ≥10% of patients, both chemotherapy related - - 84% of participants maintained or gained weight at three months - - Global Phase 3 MAPKeeper 301 trial (NCT07562152) in first-line metastatic pancreatic cancer actively recruiting, with first patient dosing expected in mid-2026 - - Company to hold investor conference call today, at 8:00 a.m. EDT - NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical
- PRImmuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related - - Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST - NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported a 17.3-month median overall survival (OS) in first-line metastatic pancreatic cancer patients treated in its Phas
- SECSEC Form 10-Q filed by Immuneering Corporation10-Q - Immuneering Corp (0001790340) (Filer)
- SECImmuneering Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immuneering Corp (0001790340) (Filer)
- PRImmuneering Reports First Quarter 2026 Financial Results and Provides Business Updates- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer now recruiting (NCT07562152),with first patient dosing on track for mid-2026 - - 27 months progression-free survival to date in a third-line pancreatic cancer patient receiving atebimetinib monotherapy, with an ongoing 85% reduction in tumor burden – - Ended Q1 2026 with $198.6 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 - NEW YORK, May 15, 2026 (G
- PRImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation will highlight data from an expanded cohort totaling 55 first-line patients - NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that updated data from the Phase 2a clinical trial evaluating atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients will be presented a
- SECSEC Form DEFA14A filed by Immuneering CorporationDEFA14A - Immuneering Corp (0001790340) (Filer)
- SECSEC Form DEF 14A filed by Immuneering CorporationDEF 14A - Immuneering Corp (0001790340) (Filer)
IMRX FAQ
6 questionsWhere does IMRX stock trade?
Immuneering Corporation (IMRX) is listed on NASDAQ.What sector and industry is IMRX in?
Immuneering Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immuneering Corporation go public?
Immuneering Corporation (IMRX) completed its IPO in 2021.What are analysts saying about IMRX?
Immuneering Corporation has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $1700.00 price target on 2026-07-08.What companies are similar to IMRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMRX side-by-side with any of them on Quantisnow.How can I track IMRX on Quantisnow?
Quantisnow aggregates Immuneering Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMRX to receive live email and push alerts on every new disclosure.